News Release

Study unlocks key to success of drug-resistant bacteria

Peer-Reviewed Publication

Columbia University Irving Medical Center

NEW YORK, NY (April 8, 2022)—Researchers have discovered how Gram-negative bacteria—which cause drug-resistant pneumonia, bloodstream infections, and surgical site infections in hospitalized patients—finish building a crucial component of their outer membrane that shields these pathogens from attacks by the immune system and antibiotics. The new findings could accelerate the development of novel drugs to counteract these potentially deadly bacteria, the source of countless infections in health care settings worldwide.

The study was published online April 6 in Nature.

“Previously, we knew that Gram-negative bacteria construct their outer membrane with two main, non-protein components—lipids and sugars—which together form an impermeable barrier. The missing link was how this lipopolysaccharide component comes together,” says Filippo Mancia, PhD, a co-leader of the study and professor of physiology & cellular biophysics at Columbia University Vagelos College of Physicians and Surgeons.

Using cutting-edge single-particle cryo-electron microscopy, Mancia and colleagues were able to determine the structures of the enzyme that links together the lipids and sugars (called an O-antigen ligase), in two different functional configurations. Then, combining genetic, biochemical, and molecular dynamics experiments, the team learned how the enzyme positions the lipids and sugars so that they can combine to form the protective membrane.

The lipopolysaccharide component of the outer membrane is critical to the survival of Gram-negative bacteria. “If you could block its assembly, then you would make the bacteria more sensitive to antibiotics and more vulnerable to the immune system,” Mancia says.

Construction of this membrane is an ongoing process, beginning when Gram-negative bacteria are first formed and continuing as the membrane naturally degrades and requires repair. “This means that we would have many opportunities to disrupt the membrane, not just at one stage of the bacteria’s life cycle,” Mancia says.

After revealing the structure of the enzyme that performs the last and critical step in assembling lipopolysaccharide barriers in drug-resistant bacteria, the researchers may begin to custom-design drugs that inhibit the biosynthesis of this protective membrane.

More information

The lead author of the study is Khuram U. Ashraf, PhD, who was until recently a postdoctoral fellow in Mancia’s lab at Columbia. The other study co-leaders are M. Stephen Trent of the University of Georgia, Athens, GA, and Phillip J. Stansfeld of the University of Warwick, Coventry, UK. Several other Columbia researchers made important contributions to this study including Rie Nygaard, PhD, Oliver Clarke, PhD, Anne-Catrin Uhlemann, MD, and Thomas McConville, MD.

The paper is titled “Structural basis of lipopolysaccharide maturation by the O-antigen ligase.” The other contributors are Owen N. Vickery (University of Warwick, Coventry, UK), Satchal K. Erramilli (University of Chicago, Chicago, IL), Carmen M. Herrera (University of Georgia, Athens, GA), Vasileios I. Petrou (Rutgers Biomedical Health Sciences, Newark, NJ), Sabrina I. Giacometti (Columbia), Meagan Belcher Dufrisne (Columbia), Kamil Nosol (University of Chicago), Allen P. Zinkle (Columbia), Chris L.B. Graham (University of Warwick), Michael Loukeris (New York Structural Biology Center, New York, NY), Brian Kloss (New York Structural Biology Center), Karolina Skorupinska-Tudek (Polish Academy of Sciences, Warsaw, Poland), Ewa Swiezewska (Polish Academy of Sciences), David I. Roper (Columbia and University of Warwick), and Anthony A. Kossiakoff (University of Chicago).

The study was funded by grants from the National Institutes of Health (GM132120, AI150098, AI138576 AI129940, GM117372, GM116799, U54 DK104309, T32 AI100852 and K08 AI146284), Wellcome, the MRC, and the BBSRC.

The authors declare no competing interests.


Columbia University Irving Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the Vagelos College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Irving Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit or

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.